LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
LGP - LITTLE GREEN PHARMA LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.59
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.16
22 Sep |
OPEN $0.16 |
HIGH $0.16 |
157,277 LOW $0.16 |
0.005| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | -3.4 |
| DPS All | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | 19.9 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | 27.6 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | -6.9 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | -43.09 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | -10.85 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | -10.25 % |
| Return on Assets | xxx | xxx | xxx | xxx | -8.80 % |
| Return on Equity | xxx | xxx | xxx | xxx | -10.85 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | -15.58 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -8.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | 7 M |
| Long Term Debt | xxx | xxx | xxx | xxx | 5 M |
| Total Debt | xxx | xxx | xxx | xxx | 12 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 12 M |
| Price To Book Value | xxx | xxx | xxx | xxx | 0.65 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | 4.9 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | 24.82 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | 12 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 22 M |
| Research & Development | xxx | xxx | xxx | xxx | 7 M |
| Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
LGP STOCK CHART
FNArena News on LGP
| 1 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 2 |
Australian Broker Call *Extra* Edition – May 08, 2023May 08 2023 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Jun 07, 2022Jun 07 2022 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Nov 10, 2021Nov 10 2021 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – Oct 05, 2021Oct 05 2021 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |
| 2 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 3 |
Momentum Keeps Building For Avita MedicalAug 15 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: IDT AustraliaAug 14 2023 - Small Caps |
| 5 |
Treasure Chest: Less Smooth Road Ahead For CSLAug 01 2023 - Treasure Chest |
| 6 |
Dr Boreham’s Crucible: Telix PharmaceuticalsJul 31 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: PolyNovoJul 06 2023 - Small Caps |
| 9 |
CSL Disappoints But Brokers Retain The FaithJun 15 2023 - Australia |
| 10 |
Dr Boreham’s Crucible: DimerixJun 07 2023 - Small Caps |
